PDCD1 and neoplasm: During the treatment of the primary tumor, CBDCA induces tumor cell death (Figure 1 and Supplemental Figure 2) and anti-PD-1 antibodies induce a very limited degree of necrosis (Supplemental Figure 2), which probably may release tumor-specific antigens to the tumor microenvironment.